Abstracts tagged "IL-6"

Abstract Number: 3222 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Monotherapy with Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study
Peter C. Taylor¹, Michael Schiff², Qingmin Wang³, Yusang Jiang³, Regina Kurrasch⁴, Shruti Daga⁵, Ravi Rao⁶, Benjamin Hsu³ and Paul-Peter Tak⁷, ¹Kennedy Institute of Rheumatology, NDORMs, University of Oxford, Oxford, United Kingdom, ²University of Colorado, School of Medicine, Denver, CO, ³Janssen Research & Development, LLC, Spring House, PA, ⁴GlaxoSmithKline, Collegeville, PA, ⁵GlaxoSmithKline, Uxbridge, United Kingdom, ⁶GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ⁷GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab, a human monoclonal antibody that selectively binds to the cytokine IL-6 with high affinity, is under development for rheumatoid arthritis (RA) and other…
Abstract Number: 911 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
John H. Stone¹, Katie Tuckwell², Sophie Dimonaco², Micki Klearman³, Martin Aringer⁴, Daniel Blockmans⁵, Elisabeth Brouwer⁶, Maria C. Cid⁷, Bhaskar Dasgupta⁸, Juergen Rech⁹, Carlo Salvarani¹⁰, Robert F. Spiera¹¹, Sebastian H. Unizony¹, Neil Collinson² and the GiACTA Investigators, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Products Ltd., Welwyn Garden City, United Kingdom, ³Genentech, South San Francisco, CA, ⁴Abteilung für Rheumatologie, Dresden, Germany, ⁵General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁶Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁸Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁹Friedrich-Alexander-University Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹¹Hospital for Special Surgery, Cornell, New York, NY
Background/Purpose: The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized,…
Abstract Number: 3223 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
Daniel Aletaha¹, Clifton Bingham III², Yoshiya Tanaka³, Prasheen Agarwal⁴, Regina Kurrasch⁵, Paul-Peter Tak⁶ and Sharon Popik⁴, ¹Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA, ⁶GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity and is under development for rheumatoid arthritis (RA)…
Abstract Number: 935 • 2016 ACR/ARHP Annual Meeting
Pretreatment Plasma IL-6 Levels Are Responsible for Bone Erosion Progression on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis
Yasushi Kondo¹, Yuko Kaneko^2,3, Hiroaki Sugiura⁴, Shunsuke Matsumoto⁴, Naoshi Nishina³, Masahiro Jinzaki⁴ and Tsutomu Takeuchi¹, ¹Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Department of Radiology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Plasma cytokines include tumour necrosis factor (TNF)-ƒ¿, interleukin (IL)-1 and IL-6 play important roles in the pathogenesis of rheumatoid arthritis (RA) causing not only…
Abstract Number: 3240 • 2016 ACR/ARHP Annual Meeting
Interferon Kappa Is a Novel Type I IFN That Drives Cutaneous Inflammation in Systemic Lupus
Jasmine Stannard¹, Tamra J. Reed², Emily Myers³, Lori Lowe⁴, Mrinal Sarkar⁴, Xianying Xing⁵, Celine C. Berthier⁶, Johann Gudjonsson⁴ and J. Michelle Kahlenberg⁷, ¹Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Rheumatology, Georgetown University, Washington, DC, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Dermatology, University of Michigan, University of Michigan, Ann Arbor, MI, ⁶Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁷Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are disfiguring, scarring, difficult to treat, and affect up to 70% of patients with systemic lupus erythematosus (SLE). Type…
Abstract Number: 798 • 2015 ACR/ARHP Annual Meeting
Keratinocyte-Associated IL-6 Is Elevated in Cutaneous Lupus Rashes and Production of IL-6 By Keratinocytes Is Enhanced in Non-Involved Lupus Skin
Jasmine Stannard¹, Emily Myers², Tamra J. Reed³, Lori Lowe⁴ and J. Michelle Kahlenberg⁵, ¹Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ²Georgetown University, Washington, DC, ³Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a devastating autoimmune disease with severe complications such as immune-complex mediated nephritis and scarring skin lesions. Treatment modalities for…
Abstract Number: 1153 • 2015 ACR/ARHP Annual Meeting
Colonic Intraepithelial Lymphocytes Produce IL-6 in Response to Resident Bacteria to Modulate Epithelial Barrier Function
Gaurav Mehta¹, Emilie H. Regner², Neha Ohri², Sean P. Colgan² and Kristine A. Kuhn², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Dysbiosis of colon bacteria has emerged as a likely contributor to diseases such as rheumatoid arthritis and spondyloarthropathies. Interactions between the microbiota and distal…
Abstract Number: 1405 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Levels and Antidrug Antibodies and Its Relationship with Disease Activity in Rheumatic Diseases
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Juana Sanint², Bibiana Quirant Sr.³, Aina Teniente Sr.⁴, Agueda Prior⁵, Anne Riveros-Frutos⁶, Susana Holgado⁷, Maria Lourdes Mateo⁷, Alejandro Olivé⁸, Jeronima Cañellas⁵ and Xavier Tena⁷, ¹Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Immunology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴immunology, Hospital Universitari Germans Trias i Pujol, barcelona, Spain, ⁵Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Microbiology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6 receptor-blocking monoclonal antibody used for the treatment of rheumatoid arthritis (RA), idiopathic juvenile arthritis (IJA) and off-label in…
Abstract Number: 1426 • 2015 ACR/ARHP Annual Meeting
The Effect of Anti-Interleukin-6 Receptor Antibody in Ovariectomized Mice
Sho Kato¹, Hiroki Wakabayashi², Taro Nakagawa³, Yohei Naito³, Takahiro Iino⁴ and Akihiro Sudo⁵, ¹Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, ²Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, ³Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ⁴Mie University Graduate School of Medicine, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ⁵Orthopaedic surgery, Mie University Postgraduate School of Medicine, Tsu-city, Japan
Background/Purpose: Osteoporotic patients with no evidence of fractures sometimes experience vague low back pain. Bone pain associated with bone metastasis may also be related to…
Abstract Number: 1530 • 2015 ACR/ARHP Annual Meeting
Neutrophil Function and Survival Unaffected in Healthy Subjects Following Single Administration of Tocilizumab
Laurence Lok¹, Jatinder Juss¹, Neda Farahi¹, Chrystalla Loutsios¹, Chandra Solanki², Adrien Michael Peters³, Sophie Dimonaco⁴, Francis Donaldson⁴, Benjamin Porter-Brown⁴ and Edwin Chilvers¹, ¹Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, ²Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, United Kingdom, ³Division of Clinical and Laboratory Investigation, Brighton and Sussex Medical School, Brighton, United Kingdom, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Decreases in circulating neutrophil counts have been observed in adults with rheumatoid arthritis (RA) and children with systemic or polyarticular juvenile idiopathic arthritis treated…
Abstract Number: 1635 • 2015 ACR/ARHP Annual Meeting
Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ) is a IL-6 receptor blockade, administered intravenously every 4 weeks and efficiently inhibits IL-6/STAT3 signaling pathway. We have previously reported the usefulness…
Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting
Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Wan-Uk Kim¹, Eun-Jin Han², Chong-Hyeon Yoon³, Ki-Jo Kim⁴, Seung-Ah Yoo⁵, Bong Ki Hong⁵ and Saseong Lee⁵, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴St. Mary's Hospital, Seoul, South Korea, ⁵Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…
Abstract Number: 1786 • 2015 ACR/ARHP Annual Meeting
Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
Vibeke Strand¹, Annette Diehl², Jared Christensen², Joseph Wajdula², Sudhakar Sridharan³ and Paul J Healey², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, New York City, NY, ³PPD Inc, Rockville, MA
Background/Purpose: The 10 mg dose of PF-04236921 showed evidence of efficacy in a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported outcomes (PROs)…
Abstract Number: 1986 • 2015 ACR/ARHP Annual Meeting
Clinical Efficacy of Tocilizumab in Polymyalgia Rheumatica: An OPEN-Label Study.
Eric Toussirot¹, Antoine Martin², Martin Soubrier³, serge redeker⁴, Alexis Régent⁵ and Le CRI⁶, ¹Service de Rhumatologie, CHU J Minjoz, Besancon, France, ²Rheumatology, Centre Hospitalier, St Brieuc, France, ³Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴43 rue de l'isle, Ch Abbeville, Abbeville, France, ⁵Paris Descartes University, UPRES-EA 4058, Paris, France, ⁶Rheumatology, CHU, Strasbourg, France
Background/Purpose: polymyalgia rheumatic (PMR) is a chronic inflammatory disorder of unknown etiology that affects elderly people. Glucocorticoids (GC) are still the mainstay of therapy for…
Abstract Number: 2017 • 2015 ACR/ARHP Annual Meeting
DNA Methylation Governs the Ability of Apoptotic Cells to Suppress Inflammatory Arthritis Via Reciprocal Regulation of IL-6 and TGF-Beta
Clare Notley¹, Christine Jordan², Jenny McGovern², Mark Brown² and Michael R. Ehrenstein³, ¹Rheumatology, UCL, London, United Kingdom, ²UCL, London, United Kingdom, ³Medicine, University College London, London, United Kingdom
Background/Purpose: Apoptotic cells (AC) have potent anti-inflammatory effects. Injection of apoptotic dendritic cells into mice suppresses the severity of antigen-induced arthritis through increased TGFβ production…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].